Audit: QRS - Star Anise for Health & Longevity

Audit conducted on 04/09/2026 03:57 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	86
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol values (ER 318/320/324), time-to-effect (ER 371), benefit and risk headings (ER 157–199, 225–253), gates (ER 271–296), monitoring table (ER 401–406), cadence (ER 397) and qualitative markers (ER 410–414) all trace to explicit ER text.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	time_1_sub “Only follow-up taken; nothing known about how much earlier the change appears” mirrors ER 371; “Relief described within hours of a single infusion in traditional use” mirrors the ER’s hedged traditional-use framing.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	All six contraindications keep the ER’s avoidance framing and their qualifiers; no caution is upgraded to a contraindication or vice versa.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates come only from ER Key Interactions & Contraindications; benefits from Expected Benefits; risks from Potential Risks & Side Effects; monitoring and qualitative items from Monitoring Protocol & Defining Success. No modifying factors are surfaced as gates.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS contains no PMIDs, citations, NCT identifiers, expert names, or brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	The measured, evidence-weighted tone of the ER Conclusion is carried through, including the culinary-versus-extract distinction.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Tiered benefit/risk labels, quantitative monitoring targets and concrete protocol values present the evidence without hedging or alarm.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as fact and range, not as instruction to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperative or prescriptive constructions; the cadence text describes documented practice rather than instructing.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No occurrence of “should”, “must”, “recommend”, or “advise” in the document body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are limited to biomarker names and the Child-Pugh class, which is glossed as “moderate to severe liver failure”.
2.8	Information is presented in a concise and very compact manner	🟢	Benefits and risks are reduced to bare tier headings; gate items carry no mechanistic rationale.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address anywhere in the QRS.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Contamination testing, estragole ceilings and biomarker targets address a risk-aware, proactive reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Twice-daily 21-day rinse protocol and a six-marker laboratory panel assume an audience willing to invest effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Content density, biomarker ranges and interaction detail exceed general-population framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance explicitly separates unremarkable culinary use from concentrated extracts, which is the distinction that matters for this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not appear in the document.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terminology is used throughout the body; the plainer wording in the at-a-glance is required by item 7.4 and remains accurate.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	Verified at lines 440, 477, 519, 537, 550, 570, 587, 591–593, 673; tier labels “Medium”, “Low”, “Speculative” unchanged at lines 523, 526, 529, 574, 577, 580.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 template variables are present; the repeatable marker_#* and qualitative_item# variables are instantiated as marker_1..6 and qualitative_item_1..5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The three website="..." spans and all template markup outside the variable spans are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the unpopulated High tiers are handled under items 12.5 and 13.5 by hiding the span.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	All eight interaction labels and the three protocol approach labels are taken verbatim from the ER bold labels (ER 271–285, 318–324).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	All twelve benefit and risk items reproduce the ER #### headings exactly; the six monitoring markers reproduce the ER Biomarker column exactly.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters occur in the file; tiering is conveyed by bold labels and the card colour classes.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed rather than extended: benefits and risks are headings only, gate items carry no rationale, and the unused time-to-effect cell is collapsed rather than padded.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> at line 1 and before the template comment at line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the descriptive text sits on line 2 before the opening delimiter.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	The block is an HTML comment and none of its values are repeated in the body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:02" is quoted, correctly so because it contains a colon; all other values are bare and trimmed.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: star_anise_2026-0904-0157_Opus_ER.md, matching the ER frontmatter filename.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0904-0350, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version with no context-window or deployment qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: star_anise_2026-0904-0157_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace and no unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: Star Anise for Health & Longevity - Quick Reference Sheet, with the ampersand correctly encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: Star Anise for Health & Longevity, matching ER frontmatter canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/04/2026, the correct MM/DD/YYYY rendering of 2026-0904-0350.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: Opus 5, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header block (lines 415–428) is identical to the template apart from the three variable substitutions; no alternate-names line was carried over from the ER.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses ER 436–440 and closes on the decision-relevant split between culinary use and concentrated extracts.
7.2	[at_a_glance] is no longer than 60 words	🟢	56 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Mouthwash result → ER 436; laboratory/animal basis → ER 436 and 153; toxic look-alike and infant seizures → ER 438; unremarkable culinary use and extract harm/benefit balance → ER 440.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “gum inflammation”, “mouth bacteria”, “laboratory and animal work” and “near-identical toxic relative” rather than gingival index, oral bacterial load, preclinical, or Illicium anisatum.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Refers only to “one small, unrepeated human trial” with no name, year, n, or p-value.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect estimate appears; the gingival index figures from ER 161 are correctly omitted.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items map to the “Populations who should avoid Star Anise” list at ER 289–296.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER avoidance populations are present, none added and none omitted.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Lines 540–545, six well-formed <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER rationale “given the estrogenic signal and the contamination hazard” (ER 293) is stripped; no dashes of any kind appear in the gate items.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Age thresholds (12 months, 5 years), the “(moderate to severe liver failure)” gloss, the Child-Pugh staging, and the preparation qualifiers for extracts and essential oils are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six avoidance populations, and the section is correctly populated rather than left empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not left empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map to the bulleted interactions at ER 271–285.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Eight of the nine ER bullets are carried; the ninth (“Other interventions: Oseltamivir. No interaction exists”) is correctly omitted as an explicit non-interaction. No item duplicates a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Lines 553–560, eight well-formed <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item is reduced to the ER bold label alone; the Caution/Monitor grading, mechanism sentences and Mitigation clauses (ER 271–285) are all stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All eight parenthetical example-drug and example-supplement lists are preserved verbatim, including “high-dose vitamin E” as a dose qualifier.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses; every parenthetical is already a plain comma-separated list.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies eight such interactions, and the section is correctly populated rather than left empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not left empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells map to bullets in ER Therapeutic Protocol at lines 318, 320 and 324.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Culinary (the dominant use), oral rinse (the only randomised-supported route) and the European traditional-medicine infusion are selected; the concentrated-extract route is correctly excluded as unsupported by any trial (ER 322).
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER describes four distinct approaches, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	“1–3 whole pods / per dish serving four” (ER 318), “3% extract, twice daily / 30 seconds over 21 days” (ER 324) and “0.5–1 g per 150 mL / up to three times daily” (ER 320) are all ER-derived.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER’s Time to effect bullet (line 371) provides exactly two distinct aspects, and both are carried; the third set is handled under item 11.3.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Gingival inflammation (Medium tier) precedes cough and digestive spasm (Low tier), matching the benefit ordering.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	🟢	The third .pcell carries style="display: none" at line 503 and its three spans are empty rather than filled with placeholder or empty-state text.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“21 days / only follow-up taken” and “Within hours / single infusion in traditional use” both derive from ER 371.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information at line 371, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All nine items reproduce #### headings from ER 157–199.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four variables are present at lines 521, 522, 525 and 528.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the benefit headings are carried; the trial description and the Magnitude figures at ER 159–161 and 167–169 are excluded.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in any benefit item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER records no High-tier benefit (line 153), and benefits_high is set to style="display: none" with empty content at line 521.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All five items reproduce #### headings from ER 225–253.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four variables are present at lines 572, 573, 576 and 579.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the risk headings are carried; the anisatin mechanism and the “roughly 40 illnesses” Magnitude figure at ER 227–229 are excluded.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in any risk item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER records no High-tier risk (line 221), and risks_high is set to style="display: none" with empty content at line 572.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	The table reproduces the ER Monitoring Protocol & Defining Success biomarker table at ER 399–406.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All six ER rows are present — ALT, AST, GGT, hs-CRP, Platelet count and INR, and Estradiol — with targets and rationales carried verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 667 condenses ER 397: baseline, liver panel at 6 weeks then every 6–12 months, inflammation marker at 12 weeks, clotting at 4 weeks, and “Unnecessary for culinary use”.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items map to the “Qualitative markers worth tracking” list at ER 410–414.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five ER qualitative markers are present, in ER order, with only the 48-hour recovery clause on the fifth item trimmed for the one-page budget.

Issues 04/09/2026 03:57

Pass rate 100.00%. No issues found.